Genetic and epigenetic alterations of Ras signalling pathway in colorectal neoplasia: Analysis based on tumour clinicopathological features

Keita Harada, Sakiko Hiraoka, J. Kato, J. Horii, Hirofumi Fujita, K. Sakaguchi, Y. Shiratori

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Activation of RAS signalling induced by K-ras/BRAF mutations is a hallmark of colorectal tumours. In addition, Ras association domain families 1 and 2 (RASSF1 and RASSF2), the negative regulators of K-ras, are often inactivated by methylation of the promoter region in those tumours. However, reports showing differences in the occurrence of these alterations on the basis of tumour characteristics have been scarce. We analysed K-ras/BRAF mutations and the methylation status of RASSF1 and RASSF2 promoter regions in 120 colorectal adenomas with respect to their clinicopathological features. K-ras/BRAF mutations and RASSF2 methylation were observed in 49 (41%) and 30 (25%) of the samples, respectively, while RASSF1 methylation was observed in only 3 (2.5%). Adenomas with RASSF2 methylation often carried K-ras/BRAF mutations simultaneously (22 out of 30, P

Original languageEnglish
Pages (from-to)1425-1431
Number of pages7
JournalBritish Journal of Cancer
Volume97
Issue number10
DOIs
Publication statusPublished - Nov 19 2007

Fingerprint

Epigenomics
Methylation
Mutation
Neoplasms
Genetic Promoter Regions
Adenoma
Colorectal Neoplasms

Keywords

  • Colorectal adenoma
  • Colorectal cancer
  • K-ras/BRAF mutations
  • Methylation
  • Ras signalling pathway
  • RASSF2

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Genetic and epigenetic alterations of Ras signalling pathway in colorectal neoplasia : Analysis based on tumour clinicopathological features. / Harada, Keita; Hiraoka, Sakiko; Kato, J.; Horii, J.; Fujita, Hirofumi; Sakaguchi, K.; Shiratori, Y.

In: British Journal of Cancer, Vol. 97, No. 10, 19.11.2007, p. 1425-1431.

Research output: Contribution to journalArticle

@article{c136b7f0d39a4df2b5baf15d64e60fc1,
title = "Genetic and epigenetic alterations of Ras signalling pathway in colorectal neoplasia: Analysis based on tumour clinicopathological features",
abstract = "Activation of RAS signalling induced by K-ras/BRAF mutations is a hallmark of colorectal tumours. In addition, Ras association domain families 1 and 2 (RASSF1 and RASSF2), the negative regulators of K-ras, are often inactivated by methylation of the promoter region in those tumours. However, reports showing differences in the occurrence of these alterations on the basis of tumour characteristics have been scarce. We analysed K-ras/BRAF mutations and the methylation status of RASSF1 and RASSF2 promoter regions in 120 colorectal adenomas with respect to their clinicopathological features. K-ras/BRAF mutations and RASSF2 methylation were observed in 49 (41{\%}) and 30 (25{\%}) of the samples, respectively, while RASSF1 methylation was observed in only 3 (2.5{\%}). Adenomas with RASSF2 methylation often carried K-ras/BRAF mutations simultaneously (22 out of 30, P",
keywords = "Colorectal adenoma, Colorectal cancer, K-ras/BRAF mutations, Methylation, Ras signalling pathway, RASSF2",
author = "Keita Harada and Sakiko Hiraoka and J. Kato and J. Horii and Hirofumi Fujita and K. Sakaguchi and Y. Shiratori",
year = "2007",
month = "11",
day = "19",
doi = "10.1038/sj.bjc.6604014",
language = "English",
volume = "97",
pages = "1425--1431",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Genetic and epigenetic alterations of Ras signalling pathway in colorectal neoplasia

T2 - Analysis based on tumour clinicopathological features

AU - Harada, Keita

AU - Hiraoka, Sakiko

AU - Kato, J.

AU - Horii, J.

AU - Fujita, Hirofumi

AU - Sakaguchi, K.

AU - Shiratori, Y.

PY - 2007/11/19

Y1 - 2007/11/19

N2 - Activation of RAS signalling induced by K-ras/BRAF mutations is a hallmark of colorectal tumours. In addition, Ras association domain families 1 and 2 (RASSF1 and RASSF2), the negative regulators of K-ras, are often inactivated by methylation of the promoter region in those tumours. However, reports showing differences in the occurrence of these alterations on the basis of tumour characteristics have been scarce. We analysed K-ras/BRAF mutations and the methylation status of RASSF1 and RASSF2 promoter regions in 120 colorectal adenomas with respect to their clinicopathological features. K-ras/BRAF mutations and RASSF2 methylation were observed in 49 (41%) and 30 (25%) of the samples, respectively, while RASSF1 methylation was observed in only 3 (2.5%). Adenomas with RASSF2 methylation often carried K-ras/BRAF mutations simultaneously (22 out of 30, P

AB - Activation of RAS signalling induced by K-ras/BRAF mutations is a hallmark of colorectal tumours. In addition, Ras association domain families 1 and 2 (RASSF1 and RASSF2), the negative regulators of K-ras, are often inactivated by methylation of the promoter region in those tumours. However, reports showing differences in the occurrence of these alterations on the basis of tumour characteristics have been scarce. We analysed K-ras/BRAF mutations and the methylation status of RASSF1 and RASSF2 promoter regions in 120 colorectal adenomas with respect to their clinicopathological features. K-ras/BRAF mutations and RASSF2 methylation were observed in 49 (41%) and 30 (25%) of the samples, respectively, while RASSF1 methylation was observed in only 3 (2.5%). Adenomas with RASSF2 methylation often carried K-ras/BRAF mutations simultaneously (22 out of 30, P

KW - Colorectal adenoma

KW - Colorectal cancer

KW - K-ras/BRAF mutations

KW - Methylation

KW - Ras signalling pathway

KW - RASSF2

UR - http://www.scopus.com/inward/record.url?scp=36148947536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36148947536&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6604014

DO - 10.1038/sj.bjc.6604014

M3 - Article

C2 - 17923875

AN - SCOPUS:36148947536

VL - 97

SP - 1425

EP - 1431

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 10

ER -